subscribeSubscribe
price-trendAsk Us
Mirati`s wait for next lung cancer med ends in phase 3 failure

Mirati`s wait for next lung cancer med ends in phase 3 failure
Annalee Armstrong FIERCE BIOTECH
25 May 2023
Share Share
Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study
PRESS RELEASE
24 May 2023
Share Share
Mirati`s sitravatinib yet to improve survival at interim review

Mirati`s sitravatinib yet to improve survival at interim review
Nick Paul Taylor FIERCEBIOTECH
02 Dec 2022
Share Share
Mirati Therapeutics Presents Ph2 Data On Sitravatinib With Nivolumab

Mirati Therapeutics Presents Ph2 Data On Sitravatinib With Nivolumab
BIOSPACE
18 Sep 2020
Share Share
Mirati`s Announces Initial Data In RCC a Sitravatinib In Combination

Mirati`s Announces Initial Data In RCC a Sitravatinib In Combination
PR NEWSWIRE
17 Feb 2020
Share Share
Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib

Mirati Therapeutics Announces Presentation Of Interim Phase 2 Sitravatinib
PR NEWSWIRE
24 Oct 2019
Share Share
Mirati Presents Ph 2 Clinical Trial Of Sitravatinib+Nivolumab

Mirati Presents Ph 2 Clinical Trial Of Sitravatinib+Nivolumab
PR NEWSWIRE
10 Nov 2018
Share Share
Mirati`s Patient Dosed In Ph1b Clinical Trial Of Sitravatinib+ Tislelizumab

Mirati`s Patient Dosed In Ph1b Clinical Trial Of Sitravatinib+ Tislelizumab
PR NEWSWIRE
10 Nov 2018
Share Share